Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Drug Therapy

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...

Treatment Strategies for Psychological Disorders

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of treating depression on quality-of-life and exercise tolerance in severe COPD.

COPD·2006

Same author

Individual dietary education reduces olanzapine associated weight gain.

Evidence-based mental health·2006

Same author

Olanzapine and weight gain.

The American journal of psychiatry·2005

Same author

Should diet be a medical intervention?

Lancet (London, England)·2004

Same author

Review: combining pindolol with an SSRI improves early outcomes in people with depression.

Evidence-based mental health·2004

Same author

Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.

Diabetes care·2004

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Treating depression with SNRIs: who will benefit most?

Michael T Isaac¹

¹South London and Maudsley NHS Trust/Institute of Psychiatry, London, United Kingdom. mi@stekel.demon.co.uk

|December 17, 2008

Summary

Serotonin-norepinephrine reuptake inhibitors (SNRIs) show promise for severe depression. Patient genetics and neurochemistry, particularly for milnacipran, influence antidepressant response and side effects.

Area of Science:

Pharmacogenomics
Neuroscience
Psychiatry

Background:

Serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine, milnacipran, and duloxetine may offer superior antidepressant activity compared to selective serotonin reuptake inhibitors (SSRIs), especially in severe depression.
Individual patient responses to SNRIs vary significantly.
Recent research investigates factors influencing milnacipran response.

Purpose of the Study:

To explore genetic and neurochemical factors affecting patient response to milnacipran.
To compare the metabolic pathways and genetic influences of milnacipran versus venlafaxine.
To assess the potential of biochemical and pharmacogenetic profiling for personalized antidepressant selection.

Main Methods:

Analysis of genetic polymorphisms related to noradrenergic neurotransmission.

More Related Videos

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Related Experiment Videos

Last Updated: Jul 3, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol

Published on: November 21, 2025

Measurement of pretreatment plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels.

Investigation of cytochrome P450 (CYP) 2D6 enzyme activity and its impact on drug metabolism.

Main Results:

Specific noradrenergic gene polymorphisms correlate with varying degrees or speed of milnacipran response.
Patients with lower baseline MHPG levels exhibit a better response to milnacipran.
Milnacipran's lack of metabolism via CYP enzymes makes it independent of CYP2D6 genetic variations, unlike venlafaxine, which is significantly affected, leading to potential adverse effects.

Conclusions:

Milnacipran demonstrates a distinct impact on the noradrenergic system, differentiating it from SSRIs and venlafaxine.
Genetic variations in CYP2D6 significantly influence venlafaxine levels and adverse effects, a factor not applicable to milnacipran.
Future clinical practice may leverage patient-specific biochemical and pharmacogenetic data to optimize antidepressant medication choices.